carvacrol has been researched along with Neointima in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, S; Jung, SH; Kim, B; Kim, DY; Kwon, SC; Lee, D; Lee, DY; Lee, GB; Lee, HM; Lee, KP; Sudjarwo, GW; Won, KJ | 1 |
1 other study(ies) available for carvacrol and Neointima
| Article | Year |
|---|---|
Carvacrol inhibits atherosclerotic neointima formation by downregulating reactive oxygen species production in vascular smooth muscle cells.
Topics: Animals; Antioxidants; Atherosclerosis; Becaplermin; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cells, Cultured; Cymenes; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Hydrogen Peroxide; Male; Monoterpenes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Neointima; Neovascularization, Physiologic; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-sis; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction | 2015 |